About 5-hydroxytryptamine receptor 1F
5-hydroxytryptamine receptor 1F (HTR1F) is a protein
from Homo sapiens identified by UniProt accession
P30939, 366 residues long.
MolForge cross-references it against 0 known binders and
76 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 1F |
| UniProt accession | P30939 |
| Gene | HTR1F |
| Organism | Homo sapiens |
| Length | 366 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (76)
Diseases linked to this target (Open Targets).
- migraine disorder · score 0.60
- schizophrenia · score 0.59
- schizoaffective disorder · score 0.50
- post operative nausea and vomiting · score 0.47
- migraine with aura · score 0.43
- depressive disorder · score 0.43
- migraine without aura · score 0.43
- pain · score 0.37
- mental or behavioural disorder · score 0.37
- movement disorder · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P30939-F1 | alphafold | PREDICTED | 83.37 | — |
Amino-acid sequence (366 residues)
MDFLNSSDQN LTSEELLNRM PSKILVSLTL SGLALMTTTI NSLVIAAIIV TRKLHHPANY LICSLAVTDF LVAVLVMPFS IVYIVRESWI MGQVVCDIWL SVDITCCTCS ILHLSAIALD RYRAITDAVE YARKRTPKHA GIMITIVWII SVFISMPPLF WRHQGTSRDD ECIIKHDHIV STIYSTFGAF YIPLALILIL YYKIYRAAKT LYHKRQASRI AKEEVNGQVL LESGEKSTKS VSTSYVLEKS LSDPSTDFDK IHSTVRSLRS EFKHEKSWRR QKISGTRERK AATTLGLILG AFVICWLPFF VKELVVNVCD KCKISEEMSN FLAWLGYLNS LINPLIYTIF NEDFKKAFQK LVRCRC
Explore 5-hydroxytryptamine receptor 1F with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets